Subscribe To
NKTR / Nektar (NKTR) Upgraded to Buy: Here's Why
NKTR News
By Zacks Investment Research
September 28, 2023
Nektar (NKTR), Cellular Biomedicine Join for Lung Cancer Studies
Nektar (NKTR) enters into a deal with Cellular Biomedicine Group to develop NKTR-255 in combination with C-TIL05 to treat advanced NSCLC. more_horizontal
By Zacks Investment Research
September 14, 2023
Nektar (NKTR) Up on Positive New Data From Eczema Study
Nektar (NKTR) gains on positive new data for its pipeline candidate, rezpegaldesleukin, evaluated from an early-stage study for treating atopic dermat more_horizontal
By Zacks Investment Research
August 14, 2023
Nektar (NKTR) Stock Surges 75% in a Week: Here's Why
Nektar's (NKTR) shares rally almost 75% in a week on corrected efficacy data for rezpeg studies, earlier miscalculated by Eli Lilly. more_horizontal
By Zacks Investment Research
August 9, 2023
Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss
Nektar (NKTR) incurs a narrower-than-expected second-quarter loss but misses on revenues. more_horizontal
By Seeking Alpha
August 8, 2023
Nektar Therapeutics (NKTR) Q2 2023 Earnings Call Transcript
Nektar Therapeutics (NASDAQ:NKTR ) Q2 2023 Earnings Conference Call August 8, 2023 5:00 PM ET Company Participants Vivian Wu - Director, Investor Rela more_horizontal
By PRNewsWire
August 1, 2023
Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets
SAN FRANCISCO , Aug. 1, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2023 on Tue more_horizontal
By PRNewsWire
June 12, 2023
Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference
SAN FRANCISCO , June 12, 2023 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside more_horizontal
By Seeking Alpha
May 9, 2023
Nektar Therapeutics (NKTR) Q1 2023 Earnings Call Transcript
Nektar Therapeutics (NASDAQ:NKTR ) Q1 2023 Earnings Conference Call May 9, 2023 5:00 PM ET Company Participants Vivian Wu - Investor Relations Howard more_horizontal